Skip to main content
Cell Death & Disease logoLink to Cell Death & Disease
. 2018 Nov 13;9(11):1126. doi: 10.1038/s41419-018-1157-x

Renal tubular epithelial cells: the neglected mediator of tubulointerstitial fibrosis after injury

Ruochen Qi 1,2, Cheng Yang 1,3,
PMCID: PMC6233178  PMID: 30425237

Abstract

Renal fibrosis, especially tubulointerstitial fibrosis, is the inevitable outcome of all progressive chronic kidney diseases (CKDs) and exerts a great health burden worldwide. For a long time, interests in renal fibrosis have been concentrated on fibroblasts and myofibroblasts. However, in recent years, growing numbers of studies have focused on the role of tubular epithelial cells (TECs). TECs, rather than a victim or bystander, are probably a neglected mediator in renal fibrosis, responding to a variety of injuries. The maladaptive repair mechanisms of TECs may be the key point in this process. In this review, we will focus on the role of TECs in tubulointerstitial fibrosis. We will follow the fate of a tubular cell and depict the intracellular changes after injury. We will then discuss how the repair mechanism of tubular cells becomes maladaptive, and we will finally discuss the intercellular crosstalk in the interstitium that ultimately proceeds tubulointerstitial fibrosis.

Facts

  • TECs are vulnerable to injury in a variety of CKDs.

  • TECs are actually participants, rather than victims or bystanders, in the progression of renal fibrosis.Please check your article carefully, coordinate with any co-authors and enter all final edits clearly in the eproof, remembering to save frequently. Once corrections are submitted, we cannot routinely make further changes to the article.Article checked

  • TECs can start repair mechanisms upon injury, though these mechanisms sometimes aggravate renal fibrosis.

  • TECs interact with other cell types in the interstitium, leading to renal fibrosis.

Note that the eproof should be amended in only one browser window at any one time; otherwise changes will be overwritten.Understood, thanks for reminding.

Open questions

  • Are TECs profibrotic or antifibrotic in the progression of tubulointerstitial fibrosis?Author surnames have been highlighted. Please check these carefully and adjust if the first name or surname is marked up incorrectly. Note that changes here will affect indexing of your article in public repositories such as PubMed. Also, carefully check the spelling and numbering of all author names and affiliations, and the corresponding email address(es).Authors' names have been checked. They are correct.

  • How do TECs change the microenvironment in the interstitium upon injury?

  • Where is the borderline between beneficial repair and maladaptive repair for TECs upon injury?

  • Are cell senescence and epithelial–mesenchymal transition different facets of the same process?

  • Is it possible to target TECs to alleviate CKDs in clinical settings in the future?

Introduction

Chronic kidney diseases (CKDs) have exerted a great burden on public health worldwide. According to the WHO estimate, CKD accounted for 1.5% of deaths worldwide in 20121. Renal fibrosis, especially tubulointerstitial fibrosis (TIF), is the inevitable outcome of all progressive CKD2, and therefore, exploring the intrinsic mechanisms of TIF is of great importance. TIF is manifested by tubular atrophy and the accumulation of extracellular matrix (ECM)3. For a long time, interests have focused on fibroblasts and myofibroblasts. However, in recent years, a growing number of studies are shedding light on the role of tubular epithelial cells (TECs) in renal fibrosis4. Evidence has shown that TECs, rather than being victims or bystanders, are probably an initiator of the TIF response to a variety of injuries5. The maladaptive repair mechanisms of TECs can be the key point of progression from acute to chronic disease6. In this review, we will focus on the role of TECs as an important mediator of TIF upon injury.Please note that after the paper has been formally accepted you can only provide amended Supplementary Information files for critical changes to the scientific content, not for style. You should clearly explain what changes have been made if you do resupply any such files.Understood. Thanks for reminding.Should you wish to order offprints, please click on www.nature.com/aj/forms/bmt_offprint_2017.pdf to download and complete the offprint form and upload the completed form along with the article.Understood. Thanks for reminding.

What are the intracellular changes of TECs upon injury?

Mitochondria dysfunction and reactive oxygen species (ROS) aggravate tubular injury

Mitochondrial impairment may aggravate TEC injury by disturbing energy metabolism and activating ROS and NLR family pyrin domain containing 3 (NLRP3)/inflammasomes (Fig. 1). A genome-wide transcriptome study on kidney biopsy specimens with TIF showed the deposition of lipid in TECs along with decreased expression of enzymes related to fatty acid oxidation (FAO)7. Inhibition of FAO leads to a fibrotic phenotype change in TECs, while restoring FAO attenuates TIF7. The impairment of FAO is attributed to the downregulation of peroxisome proliferator-activated receptor α  and overexpression of miR-21810. The loss of FAO also drives a metabolic switch to glycolysis in TECs to meet energy demands11. Impaired mitochondrial function also leads to the production of ROS and oxidative stress in TECs8, 12. Studies on diabetic nephropathy (DN) show that the accumulation of advanced oxidation protein products (AOPPs) results in mitochondrial injury and oxidative stress12. Production of ROS in the mitochondria can further lead to the activation of NLRP31315. Two earlier studies showed increased mitochondrial ROS production along with NLRP3/inflammasome activation. Inhibition of mitochondrial ROS production simultaneously inhibits the activation of NLRP3 and downstream interleukin-1β (IL-1β) and IL-18 production, indicating the presence of mitochondrial ROS prior to the activation of NLRP313, 14,. A recent study showed that this process is probably mediated by the mROS–TXNIP–NLRP3 pathway15. Mitochondrial ROS can also increase the expression of several other proinflammatory and profibrotic factors, including monocyte chemoattractant protein-1 (MCP-1), plasminogen activator inhibitor and transforming growth factor beta 1 (TGF-β1)16.Please define NLRP3 at its first mention in text.NLRP3 stands for NLR family pyrin domain containing 3Please spell out PPARα in text, as it is mentioned only once.PPARalpha stands for peroxisome proliferator-activated receptor α

Fig. 1. A schematic view of intracellular changes in tubular cells upon injury.

Fig. 1

Mitochondria undergo metabolic disorders, manifested by decreased fatty acid oxidation. Mitochondria can also produce ROS and further activate the NLRP3/inflammasome. Production of mitochondrial ROS is also related to the expression of proinflammatory factors. ER stress caused by misfolded proteins can start the unfolded protein reaction (UPR), including activation of GRP78 and downstream signaling, including the PERK–eIF2–ATF4 pathway and ATF6 pathway. However, persistent activation of UPR can result in apoptosis. Autophagy plays a dual role. This process can either avoid apoptosis or aggravate renal fibrosis, depending on different situations. Injuries can also lead to epigenetic changes and changes in mRNA expression

These results indicate that improving normal mitochondrial function may attenuate renal fibrosis. Recent studies prove the potential renoprotective role of several intrinsic modulation factors that are closely related to mitochondrial function. Either downregulation of dynamin-related protein 1 17 or upregulation of NAD-dependent deacetylase sirtuin-3, mitochondrial 18 or TNF receptor associated protein 1 19 could have a protective effect on mitochondrial function in TECs and ameliorate renal fibrosis.Please spell out DRP117, SIRT318 and TRAP1in text, as it is mentioned only once.DRP1 stands for dynamin-related protein 1SIRT3 stands for NAD-dependent deacetylase sirtuin-3, mitochondrialTRAP1 stands for TNF receptor associated protein 1 (TRAP1)

Endoplasmic reticulum (ER) stress and unfolded protein response (URP) are double-edge swords in tubular injury

Injuries by toxins, albuminuria, and metabolic disorders lead to accumulation of misfolded proteins in TECs and ER stress. ER stress is manifested by UPR20, an intrinsic adaptive process that helps cells survive. However, persistent activation of UPR may finally lead to apoptosis21.

GRP78, a molecular chaperone that functions in protein folding, makes UPR a pro-survival mechanism (Fig. 1). In an age-related proteinuria model, more severe TIF was observed in the aged group, together with a significantly suppressed GRP78 level, indicating the protective role of GRP7822. The binding of misfolded protein to GRP78 can start three pathways, the PRKR-like endoplasmic reticulum kinase-eukaryotic translation initiation factor 2-activating transcription factor 4 (PERK–eIF2–ATF4) pathway, inositol-requiring enzyme 1-X-Box binding protein 1  pathway and activating transcription factor 6  pathway, which in turn can activate UPR and mediate cell repair23. A recent study has also found the involvement of the mitogen-activated protein kinase (MAPK/ERK) pathway in ER stress24. However, persistent injury and UPR activation can lead to cell apoptosis. This process is mediated by caspase-12, an ER-specific caspase, via activation of the caspase-9/caspase-3 cascade20. A recent study has also shed light on the profibrotic role of a novel ER-associated protein, RTN1A21, 25. RTN1A is related to prolonged ER stress and apoptosis of TECs25. Specific knockout of RTN1A in TECs could downregulate ER stress signaling and ameliorate ER stress-associated apoptosis21.Please define PERK–eIF2–ATF4, IRE1-XBP1, ATF6, MAPK/ERK at its first mention in text.PERK–eIF2–ATF4 stands for PRKR-like endoplasmic reticulum kinase-eukaryotic translation initiation factor 2-activating transcription factor 4IRE1–XBP1 stands for inositol-requiring enzyme 1-X-Box binding protein 1ATF6 stands for activating transcription factor 6MAPK/ERK stands for mitogen-activated protein kinase

Recognition of these facts has also offered some possible approaches for the diagnosis and treatment of renal fibrosis. Urinary cysteine-rich with EGF-like domains 2, a molecule induced and secreted upon ER stress from podocytes and TECs, could be a prospective predictor of tubulointerstitial injury26. The chemical chaperon sodium 4-phenylbutyrate can mimic the role of an ER chaperone in vivo and greatly reduce TECs apoptosis and renal fibrosis caused by ER stress27. Another molecule, HMG-CoA reductase degradation 1 homolog , an E3 ubiquitin ligase, can also ameliorate TEC apoptosis by promoting ubiquitylation and degradation of eIF2alpha, a critical protein in the PERK–eIF2alpha–ATF4–CHOP signaling pathway28.Please spell out HRD1 in text, as it is mentioned only once.HRD1 stands for HMG-CoA reductase degradation 1 homolog

Autophagy exerts bidirectional effects on TECs upon injury

Autophagy is a mechanism that engulfs unnecessary or dysfunctional cellular components and can help TECs adapt to a variety of injuries;2931 however, persistent activation of autophagy leads to fibrosis (Fig. 1). In DN, the specific inhibition of autophagy results in the accumulation of advanced glycation end products along with worsened inflammation and fibrosis29. Two other studies focusing on DN also found an association between decreased autophagy and renal fibrosis, and this process is probably the result of inhibition of phosphatase and tensin homolog  by Notch1/Hes1 in response to high glucose concentrations32, 33. Another in vitro study showed that enhanced autophagy ameliorates fibrosis induced by TGF-β130. Increased autophagy is observed along with decreased apoptosis31. One study has also shown that autophagy is partly regulated by ER stress to improve renal function and histology34.Please spell out PTEN in text, as it is mentioned only once.PTEN stands for phosphatase and tensin homolog

Two studies focusing on the role of Atg5 had controversial results35, 36. One showed that genetic deletion of Atg5-mediated autophagy specifically in TECs leads to marked cell cycle arrest, increased COL1 deposition, and severe interstitial fibrosis in an unilateral ureteral obstruction (UUO) model37. However, the other study on Atg5 indicated that the ablation of autophagy in TECs leads to significantly less tubular senescence and reduced interstitial fibrosis 30 days after ischemia–reperfusion injury35. Moreover, another study investigating kidney proximal tubule-specific Atg7 knockout mice also showed ameliorated tubular injury and TIF36. These results indicate the two-way effect of autophagy in renal fibrosis. Indeed, autophagy can degrade unnecessary or dysfunction components and prevent cell apoptosis. However, some severely damaged TECs that should have undergone apoptosis may also manage to survive via autophagy. These cells undergo maladaptive repair and phenotype changes, thereby becoming sources of proinflammatory and profibrotic cytokines, leading to aggravated renal fibrosis35.Please define UUO at its first mention in text.UUO stands for unilateral ureteral obstruction

Epigenetic changes in TECs provide new therapeutic insights

One study on DN revealed a switch in DNA methylation and changes of mRNA expression of select genes, thereby leading to phenotype changes of TECs38. Another study showed increased H3K9 histone markers after UUO, indicating that epigenetics may play a role in fibrogenesis39. The possible involvement of epigenetics provides a new aspect of treatment for renal fibrosis (Fig. 1). Two research groups using either MS 275 or valproic acid  demonstrated that the class I histone deacetylase  inhibitor could effectively ameliorate renal fibrosis caused by UUO40, 41. A recent study applied DZNep (3-deazaneplanocin A), an H3K27me3 inhibitor, in an ischemia–reperfusion model. TECs harvested from the model were examined with high-throughput sequencing (RNA-seq). The study showed that profibrotic genes such as COL3A1 (collagen type 3a1) and TIMP2 (tissue inhibitor of metalloproteinase 2) are suppressed by DZNep in vivo42, demonstrating the efficacy of the treatment at the RNA level. Epigenetic changes in TECs may be an important research area for investigating the mechanisms of, or the therapeutic approaches for, renal fibrosis.Please spell out MS 275, VPA and HDAC in text, as it is mentioned only once.Both MS 275 and VPA are drugs used as HDAC inhibitor.MS 275 is the name of the drug, not an abbreviation.VPA stands for valproic acid.HDAC stands for histone deacetylase.Per style, gene names have to be italicized. Hence, COL3A1 and TIMP2 have been italicized where mentioned as genes. Please confirm that the italicization is appropriate and also mark if there are further instances that need to be italicized.Genes are italicized, thanks for reminding.

Important signaling pathways involved in renal fibrosis

A great number of intracellular pathways are involved in TECs upon injury (Table 1), of which the TGF-beta1/Smad3 pathway4345, RAS pathway4648, and Wnt/beta-catenin pathway49, 50 are the most well established. In addition to these, several other pathways are also involved, including the p38 MAPK pathway24, 51, 52, phosphatidylinositide 3-kinases/protein kinase B  pathway5357, epidermal growth factor receptor (EGFR) pathway5860, Hippo-Salvador pathway61, Notch pathway33, 62, c-Jun N-terminal kinases (JNK) pathway63, Sonic hedgehog pathway64, adiponectin/adiponectin receptor 1  pathway65, membrane rafts–redox pathway, etc66. Each signaling pathway may exert partial influences that drive the cell to play either a profibrotic or antifibrotic role, whereas different pathways can interact with each other at different levels, forming an intricate signaling network that regulates the progression of renal fibrosis after different injuries. The fact that the signaling pathways regulating renal fibrosis are still not well understood urges thorough investigation. A more comprehensive description of the regulation network will provide us with more potential targets for preventing or even reversing renal fibrosis.

Table 1.

Important signaling pathways involved in renal fibrosis

Signaling pathway Role in renal fibrosis Reference
TGF-beta1/Smad3 pathway Profibrotic 4345
RAS pathway Profibrotic and antifibrotic 4648
Wnt/beta-catenin pathway Profibrotic and antifibrotic 49, 50
P38 MAPK pathway Profibrotic 24, 51, 52
PI3K/AKT pathway Profibrotic 5357
EGFR pathway Profibrotic and antifibrotic 5860
Hippo-Salvador pathway Antifibrotic 61
Notch pathway Profibrotic 33, 62
JNK pathway Profibrotic 63
Sonic hedgehog pathway Profibrotic 64
APN/AdipoR1 pathway Profibrotic 65
Membrane rafts–redox pathway Profibrotic 66

How do repair mechanisms become maladaptive and result in renal fibrosis?

TECs can adopt different mechanisms upon insult and manage to regenerate and regain normal kidney function if the injury is mild and transient67, 68. However, if the injury is severe and persistent, normal regeneration mechanisms may not function, and TECs might undergo maladaptive repair, exacerbating renal fibrosis67, 69, 70 (Fig. 2). Renal fibrosis can be seen as the final consequence of improper repair mechanisms, in other words, maladaptive repair. A recent study demonstrated that it is the severity and frequency of TEC injury that determine whether the repair mechanism leads to recovery or progression to fibrosis71. Although adaptive repair shows profound proliferation of TECs68, the maladaptive response is characterized by interstitial fibrosis, tubular atrophy, and capillary rarefaction69.

Fig. 2. Description of maladaptive repair.

Fig. 2

It is the severity and frequency of the injury that determine whether the repair mechanism adopted by tubular cells is beneficial or maladaptive. Severe and persistent injury exceeds normal repair mechanisms, and these cells become maladaptive to survive the injury. Maladaptive repair is manifested by cell cycle arrested at the G2/M phase and a senescence-associated secretory phenotype. The former is characterized by the expression of proteins that include p53, p21, and p16INK4a. The latter includes secretion of proinflammatory and profibrotic factors, including TGF-beta1, CTGF, CXCL1, IL-6, IL-8, etc. Tubular cells can also undergo EMT to avoid apoptosis, with loss of some epithelial markers (E-cadherin, ZO-1) and acquisition of partial myofibroblast markers (alpha-SMA, vimentin, FSP-1). This process involves changes in the immune microenvironment. Proinflammatory factors secreted by TECs recruit and activate different inflammatory cells, and these recruited cells can further produce cytokines that drive TECs to undergo EMT. TECs finally obtain a myofibroblast phenotype, express alpha-SMA, and are responsible for collagen synthesis and ECM deposition

Cell senescence is the marker for maladaptive tubular cells

Maladaptive tubular cells manifest cell senescence6870, which is defined as the absence of the ability to divide and a permanently arrested cell cycle68, 72. The senescence of tubular cells has been observed in CKDs induced by hypertension, diabetes, and IgA nephropathy67. Senescence is also observed in cell ageing. Aged mice cells have decreased cellular proliferation and increased senescence compared with young mice subjected to ischemia–reperfusion injury73. A proteomic study on human proximal TECs also shows increased senescence in older cells74. Senescence has two characteristics, cell cycle arrest at the G2/M phase and the secretion of proinflammatory and profibrotic factors;67, 68, 70 the latter is also known as senescence-associated secretory phenotype. These two changes are the bridges that link tubular cell senescence with renal fibrosis.

An arrested cell cycle at the G2/M phase promotes renal fibrosis

As mentioned above, cell cycle arrest is one of the most important characteristics of cell senescence. It is the consequence of maladaptive repair by tubular cells and has a strong correlation with renal fibrosis. In uninjured kidneys, most tubular cells remain in the quiescent G0 phase. Upon insult, TECs enter the cell cycle to regenerate and replace the cells lost during injury4. Some cells are arrested at the G1 or G2 phase for DNA repair. However, persistent cell cycle arrest is a kind of maladaptive repair and has a strong association with the progression of renal fibrosis67, 68, 70. The fact that aged mice have more severe cellular senescence and fibrosis after AKI can also be explained by the increased number of cells arrested at the G2/M phase due to increased DNA damage73.

P53, p21, and p16INK4a have been recognized as the most important factors involved in this process5, 68, 69. P21 is upregulated shortly after acute kidney injury (AKI). It is renoprotective in the early phase since it can halt the cell cycle to repair DNA damage, which prevents tubular cells from undergoing apoptosis69. The fact that p21 knockout mice have more severe damage after AKI also demonstrates the protective role of p21 in the early-phase after injury68. However, persistent expression of p21 and cell cycle arrest may lead to cell senescence and aggravate fibrosis. Apart from AKI, hypoxia can also induce p21 expression and lead to G2/M phase arrest via the ataxia-telangiectasia-mutated-ataxia telangiectasia and Rad3-related R pathway69. P16INK4a is also upregulated in tubular cells upon injury and is responsible for mediating cell cycle arrest, since deleting p16INK4a could restore cell proliferation after AKI69. P53, the upstream regulator of p21, is also upregulated after AKI, and inhibition of p53 expression attenuates renal fibrosis68. P53 is also activated in DN, and its activity is in negative correlation with renal function75. Apart from p53, p21, and p16INK4a, modulation of cell cycle arrest involves more complex mechanisms. Atg5-mediated autophagy in TECs can ameliorate renal fibrosis by blocking G2/M phase arrest37. Macrophage migration inhibitory factor also counteracts cell cycle arrest76. On the other hand, miR-192 and Numb can aggravate cell cycle arrest and renal fibrosis either by upregulating or stabilizing p5377, 78. Cell cycle arrest is also correlated with the process of epithelial–mesenchymal transition (EMT), and overexpression of Twist1 or Snail is sufficient to prolong the G2/M arrest induced by TGF-β179.Please define AKI at its first mention in text.AKI stands for acute kidney injuryPlease spell out ATM, ATR in text, as it is mentioned only once.ATM-ATR stands for ataxia-telangiectasia-mutated-ataxia telangiectasia and Rad3-related

The arrested tubular cells can express factors like TGF-β1, connective tissue growth factor (CTGF), C-X-C motif chemokine ligand 1 (CXCL1), IL-6, and IL-8, partially mediated by the JNK pathway70. These factors promote a chronic inflammatory microenvironment that favors fibrosis67. Arrested tubular cells also fail to regenerate to replace the lost cells, leaving space for the proliferation of fibroblasts and deposition of ECM. All of these changes drive the interstitium to fibrosis and aggravate renal function.Please define CXCL1 at its first mention in text.CXCL1 stands for C-X-C motif chemokine ligand 1

EMT is a potential source of fibroblasts and ECM

EMT is referred to as the process that allows a polarized epithelial cell to assume a mesenchymal phenotype, which includes an enhanced migratory capacity, invasiveness, elevated resistance to apoptosis, and increased production of ECM components80. As mentioned above, TECs undergo dedifferentiation and regeneration to produce new tubular cells after injury. Meanwhile, they produce various factors that attract inflammatory cells to the tubulointerstitial space. Infiltrating cells express cytokines that further alter the tubulointerstitial microenvironment and force TECs to turn to a mesenchymal phenotype to adapt to these changes and avoid apoptosis5, 72. Moreover, this switch is also a potential source of fibroblasts and ECM deposition. Thus, the process of EMT becomes maladaptive and aggravates renal fibrosis.

EMT is characterized by the loss of epithelial markers, including E-cadherin and zonula occludens-1 (ZO-1), and the acquisition of mesenchymal markers, including vimentin, alpha-SMA, fibroblast-specific protein-1 (FSP-1), collagen I and fibronectin81. Though it is widely accepted that EMT can be induced by TGF-β1 in vitro, whether this process contributes to the production of fibroblasts in vivo is still uncertain82. A possible explanation for this controversy could be changes in the definition of EMT2. In the past, researchers expected to find complete EMT in vivo, with the complete loss of epithelial markers and the acquisition of mesenchymal markers along with tubular cells traversing the basement membrane83, 84. However, recent research has shown that EMT, rather than an “all or none” process, is actually a spectrum of changes2, 4, 5. Tubular cells could lose some epithelial makers while acquiring partial mesenchymal markers. This process is termed partial EMT, which is more likely to occur in vivo2.

Snail and Twist1 mediate this process53, 85, 86. Conditional deletion of Snai1 or Twist1 in TECs leads to inhibition of EMT79. The signaling pathway involved is complicated and overlaps with the pathways mediating renal fibrosis discussed above, including the TGF-β1/Smad pathway, intergrin/integrin linked kinase  pathway, Wnt/beta-catenin pathway, p38 MAPK pathway, Sonic hedgehog pathway, and membrane rafts–redox pathway, etc.51, 64, 81, 87. TECs undergoing this phenotypic switch can attract inflammatory cells and activate fibroblasts and pericytes in a paracrine manner;4, 79 evidence also shows that they can serve as a direct producer of ECM that can aggravate TIF88.Please spell out ILK in text, as it is mentioned only once.ILK stands for integrin linked kinase

EMT and cell senescence, manifested by G2/M phase arrest, actually have much in common. Both occur after persistent injury and maladaptive repair; both go through the process of dedifferentiation, and the secretion of proinflammatory and profibrotic cytokines, which aggravates renal fibrosis, is seen in both. Though not confirmed by experiments, it may be reasonable to infer that they are both the consequences of maladaptive repair. Moreover, they may even be two inseparable facets of the same process, with EMT emphasizing phenotypic changes and senescence emphasizing cell cycle changes. However, more research is needed to prove a correlation between EMT and cell senescence and to provide new insights into therapeutic approaches for targeting maladaptive repair mechanisms.

Though most of the researches discussed above were conducted in native kidneys, the unique nature of kidney transplantation, for example, the ischemia injury during harvesting the kidney, immune-mediated injury, use of immunosuppressants, and sequential protocol biopsies make allograft an ideal target studying the correlation between TECs and renal fibrosis. The term “interstitial fibrosis/tubular atrophy (IF/TA)” is often used in transplant biopsies, given that these two phenomena almost inevitably occur in parallel89, 90. Most of the underlying mechanisms discussed above are also confirmed in allograft studies. Take EMT for example, extensive biopsy studies have demonstrated the mesenchymal phenotype change of tubular cells in vivo, which contributes to the progression of fibrosis in the allograft and is predictive for graft loss9193. Growing numbers of studies are focusing on counteracting TIF to extend graft survival time. Mesenchymal stem cells have been confirmed to play a renoprotective role in transplanted kidneys by attenuating tubular atrophy and TIF9496. Given the unique characteristics, renal allograft might be a promising model studying renal fibrosis in the future.

How do TECs interact with other cell types in the interstitium to advance renal fibrosis?

Growing evidence has shown that TECs are indispensable mediators in TIF; they must interact with other cells in the interstitium, including inflammatory cells, endothelial cells, fibroblasts, and pericytes, to drive the progression of fibrosis. Maladaptive TECs can either attract or activate these cells via crosstalk, and these interactions together cause the progression of TIF (Fig. 3).

Fig. 3. Interactions between TECs and other cells in the interstitium.

Fig. 3

TECs can secrete CCL2 and CCL5 to recruit monocytes. Monocytes/macrophages can further produce proinflammatory factors, but their functions depend on their polarization phenotypes. Monocytes can also induce EMT by producing MMP-9. Capillary rarefaction causes hypoxia in tubular cells. Injured TECs thus secrete HIF-1alpha and VEGF to stimulate new capillary formation to meet their oxygen demand. However, these new capillaries are often leaky and are incapable of performing normal functions, thus forming a vicious cycle. Maladaptive TECs can produce a microenvironment suitable for fibroblast recruitment and activation. Activated myofibroblasts can mediate ECM deposition and execute the final process of renal fibrosis. Increased matrix rigidity can also aggravate tubular hypoxia and the progression of EMT

Crosstalk between TECs and inflammatory cells

Inflammation has been widely observed in a variety of CKD biopsy specimens and animal models and has been recognized as crucial for the initiation of renal fibrogenesis2. Among the inflammatory cells, the role of monocytes/macrophages is the most well-established.

Maladaptive TECs can secrete CCL2 and CCL5 to recruit monocytes and macrophages9799. Peripheral monocytes that are recruited can differentiate into macrophages once they arrive at the renal interstitium98. Interestingly, a recent study demonstrates that recruited monocytes could instruct TECs to turn off chemokine secretion and downregulate the production of proinflammatory factors;98 this self-limited negative feedback system indicates that monocyte may also play an important role in the resolution of inflammation. TECs can also recruit macrophages by secreting matrix metallopeptidase 9 (MMP-9) in the early stage after UUO, whereas recruited macrophages produce more MMP-9, which can aggravate the progression of EMT100.Please define MMP-9 at its first mention in text.MMP-9 stands for matrix metallopeptidase 9

Once recruited, macrophages exert pleiotropic effects on renal fibrosis depending on the polarization form: a proinflammatory M1 phenotype or a reparative M2 phenotype2. It has been well documented that, shortly after AKI, predominant M1 macrophages can amplify damage, whereas the later M2 phenotype is responsible for repair67, 99. However, persistent appearance of M2 macrophages leads to improper repair and is strongly correlated with fibrosis in CKD99. Transformation of the macrophage phenotype is determined by the microenvironment in the interstitium.

Activated macrophages produce a variety of molecules, including tumor necrosis factor-alpha, platelet-derived growth factor (PDGF), basic fibroblast growth factor (FGF-2), TGF-β, and ROS, which induce further inflammation and fibrosis101. Soluble uric acid can stimulate the NLRP3 inflammasome/IL-1β pathway in macrophages and in turn activates cytokine production in tubular cells102. Again, the effects of macrophages on tubular cells and renal fibrosis depend on the polarization phenotype, as well as the stages after injury.Is the insertion of ‘tumor necrosis factor’ as the definition of ‘TNF’ correct?Yes, TNF stands for tumor necrosis factor.

The effects of other inflammatory cells on fibrogenesis are less clear. It has been shown that T cells may play an initiation role in inflammation, as they precede the influx of macrophages into the kidney after injury2. High glucose-induced macrophage inflammatory protein-3 alpha from TECs is responsible for recruiting CD3+ cells to the interstitium103. A recent study has shed new insight on the roles of different subpopulations of T cells104. Researchers found that the depletion of either CD4+ or CD8+ T cells leads to aggravated renal fibrosis104. Accumulation of B cells in the kidney can promote monocyte/macrophage recruitment by the secretion of CCL2, thus aggravating renal fibrosis. NK cells and C3aR+ cells are also positively correlated with TIF, but the mechanisms involved remain unclear105, 106.

The complement is also activated during renal fibrosis107. An increased C5a level is observed in tubular cells in DN and is positively correlated with disease progression108. Local synthesis of the complement is also observed in PDGFRbeta-positive pericytes and CD45 (+) cells in the interstitium109. Thus, blocking synthesis or activation of the complement at different levels may offer benefits for renal fibrosis107. Tubular cells may also be part of the innate immune response. Released damage-associated molecular patterns can activate TECs by binding to their pattern recognition receptor, such as TLRs. Activated TECs can then produce cytokines or undergo pyroptosis, thus forming an auto-amplification loop of tubulointerstitial inflammation5.

Crosstalk between TECs and the microvasculature

Intact microvasculature is a prerequisite for normal tubular structure and function. Peritubular capillaries and tubular cells are often injured together during renal injuries. Loss of peritubular capillaries is strongly correlated with renal fibrosis. A decrease in CD34+ tubulointerstitial capillaries is observed together with TIF in the UUO model73, 110. However, it is hard to determine whether pericapillary injury is the cause or consequence of renal fibrosis. Capillary rarefaction results in hypoxia in tubular cells, thereby increasing oxidative stress in the interstitium. This, in turn, aggravates the damage in the microvasculature, forming a vicious cycle75. Tubular cells demand oxygen to fulfill their normal functions. Hypoxia-inducible factor-1alpha (HIF-1alpha) and its downstream vascular endothelial growth factor (VEGF) are upregulated in TECs during hypoxia111. VEGF plays a dual role in the microvasculature. As a pro-angiogenic factor, it promotes endothelial cell survival and proliferation, thus enhancing peritubular capillary density112. However, excessive VEGF may result in the formation of leaky and nonfunctional vessels, which further aggravates hypoxia and oxidative stress in the interstitium99. Additionally, it is reported that VEGF can act as a proinflammatory factor that exacerbates renal fibrosis99. Secretion of anti-angiogenic factors, such as endostatin and thrombospodin-1, by TECs can lead to microvasculature damage72, and this demonstrates the protective role of VEGF. Angiopoietin-1, a secreted vascular growth factor, ameliorates capillary rarefaction when overexpressed in TECs113.Please define HIF-1alpha at its first mention in text.HIF-1alpha stands for Hypoxia-inducible factor-1alpha

The close contact of pericytes with the endothelium is also important in maintaining capillary stability. A recent study demonstrates that ablation of pericytes alone could lead to endothelial damage and capillary rarefaction and further causes subclinical tubular cell injury, which is detected by expression of kidney injured molecule-1 and vimentin in TECs114. It is also reported that pericytes are a potential source of myofibroblasts. Pericytes can undergo a phenotype switch similar to EMT and acquire myofibroblast characteristics upon injury115. Thus, detachment of pericytes from the capillaries may further aggravate capillary rarefaction by forming more myofibroblasts.

Crosstalk between TECs and fibroblasts/myofibroblasts

Fibroblasts and myofibroblasts are the final executors of renal fibrosis. Upon injury, maladaptive TECs give rise to a switch in the microenvironment in the tubulointerstitial space in which myofibroblasts are activated. These activated executors are capable of producing substantial ECM, leading to TIF. TECs and myofibroblasts are at the two ends of the progression of renal fibrosis, the former as the initial reactor after injury and the latter as the final executor. Thus, understanding the crosstalk between these two cell types is of great importance.

Myofibroblasts are the activated form of fibroblasts, and they are characterized by the expression of alpha-smooth muscle actin (alpha-SMA), proliferation, and matrix production2. Recent studies have suggested five major origins of myofibroblasts, including resident fibroblasts, TECs, endothelial cells, pericytes, and bone marrow-derived fibrocytes2, 4, 115. However, the exact contribution of each origin to renal fibrosis remains unclear. Tsutomu et al. reviewed several lineage-tracing experiments and found conflicting results regarding the contribution of EMT to renal fibrosis82. They proposed that the controversial results might be attributed to different disease models, mouse strains and types of genetic alterations used. They further demonstrated this hypothesis with four different models and confirmed that EMT-derived fibroblasts are activated in a disease-specific and strain-dependent manner82. In other words, in different conditions, the five origins of fibroblasts account for different proportions of intrarenal myofibroblasts. The different results could also be accounted for the inherent heterogeneity of myofibroblasts2, 115. The heterogeneity of myofibroblasts also leads to the lack of a specific marker to identify myofibroblasts2.

Despite the conflicting origins, it has been a common view that myofibroblasts are mainly activated by a variety of cytokines and growth factors produced by TECs in a paracrine manner, including TGF-beta1, Wnt ligands, PDGF, hedgehog, hepatocyte growth factor, CTGF, and angiotensin II99, 116118. Recent studies have shed light on some new factors produced by TECs, such as FGF-23. According to a recent study, FGF-23 could activate myofibroblasts derived from obstructed kidneys but fail to activate fibroblasts derived from normal kidneys119. FGF-23 could also induce ECM production in rat renal TECs (NRK-52E) via the TGF-β1 pathway120. Another study using immunofluorescence analysis also confirmed that TECs can act as an efficient producer of stable ECM88. The EGFR pathway is also involved in the TEC-fibroblast crosstalk. Persistent epithelial-specific activation of EGFR leads to epithelial dedifferentiation and cell cycle arrest, along with promoting proliferation of alpha-SMA+ myofibroblasts59.

On the other hand, activated myofibroblasts can also exert profibrotic effects on tubular cells. Accumulation of ECM results in increased matrix rigidity and other biomechanical changes in the interstitium, which in turn leads to augmented levels of TGF-β1 expression and EMT121. ECM can also increase the diffusion distance of oxygen, thereby worsening hypoxia in TECs4. Microvesicles derived from fibroblasts can deliver miR-34a to tubular cells and induce tubular cell apoptosis122.

Final considerations

Growing numbers of studies have demonstrated that the long-neglected TECs are important mediators of TIF after injury. TECs can adopt different repair mechanisms to survive injury and recover normal kidney function. However, long-lasting stress makes these mechanisms maladaptive. The completion of fibrosis depends on crosstalk between TECs and other cells in the interstitium. Understanding the importance of TECs can help us further comprehend the complicated mechanisms of renal fibrosis. In the future, TECs may become new therapeutic targets to ameliorate or even reverse this process. Further investigations are needed in this field to explore the elaborate changes in TECs upon injury and how they interact with other cells to mediate renal fibrosis.

Acknowledgements

This study was supported by the National Key R&D Program of China (2018YFA0107502 to C.Y.), National Natural Science Foundation of China (grant 81400752 and 81770746 to C.Y.), and the Medical and Health Talents Training Plan for the Excellent Youth of Shanghai Municipal (2018YQ50 to C.Y.).

Authors’ contributions

C.Y. conceived and designed the review. R.Q. collected literature, analyzed literature, and wrote the draft manuscript. C.Y. helped to revise the manuscript. All authors read and approved the final manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

Footnotes

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Edited by A. Linkermann

References

  • 1.Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389:1238–1252. doi: 10.1016/S0140-6736(16)32064-5. [DOI] [PubMed] [Google Scholar]
  • 2.Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat. Rev. Nephrol. 2011;7:684–696. doi: 10.1038/nrneph.2011.149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Tanaka T. A mechanistic link between renal ischemia and fibrosis. Med. Mol. Morphol. 2017;50:1–8. doi: 10.1007/s00795-016-0146-3. [DOI] [PubMed] [Google Scholar]
  • 4.Gewin LS. Renal fibrosis: primacy of the proximal tubule. Matrix Biol. 2018;68-69:248–262. doi: 10.1016/j.matbio.2018.02.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Liu BC, Tang TT, Lv LL, Lan HY. Renal tubule injury: a driving force toward chronic kidney disease. Kidney Int. 2018;93:568–579. doi: 10.1016/j.kint.2017.09.033. [DOI] [PubMed] [Google Scholar]
  • 6.Bonventre JV. Maladaptive proximal tubule repair: cell cycle arrest. Nephron. Clin. Pract. 2014;127:61–64. doi: 10.1159/000363673. [DOI] [PubMed] [Google Scholar]
  • 7.Kang HM, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat. Med. 2015;21:37–46. doi: 10.1038/nm.3762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Chen W, et al. Atgl gene deletion predisposes to proximal tubule damage by impairing the fatty acid metabolism. Biochem. Biophys. Res. Commun. 2017;487:160–166. doi: 10.1016/j.bbrc.2017.03.170. [DOI] [PubMed] [Google Scholar]
  • 9.Chung KW, et al. Impairment of PPARalpha and the fatty acid oxidation pathway aggravates renal fibrosis during aging. J. Am. Soc. Nephrol. 2018;29:1223–1237. doi: 10.1681/ASN.2017070802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Li S, et al. Proximal tubule PPARalpha attenuates renal fibrosis and inflammation caused by unilateral ureteral obstruction. Am. J. Physiol. Ren. Physiol. 2013;305:F618–F627. doi: 10.1152/ajprenal.00309.2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Lan R, et al. Mitochondrial pathology and glycolytic shift during proximal tubule atrophy after ischemic AKI. J. Am. Soc. Nephrol. 2016;27:3356–3367. doi: 10.1681/ASN.2015020177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Li, X. et al. Advanced oxidation protein products aggravate tubulointerstitial fibrosis through protein kinase C-dependent mitochondrial injury in early diabetic nephropathy. Antioxid. Redox Signal (2018). doi: 10.1089/ars.2017.7208.Please provide the volume nmber and page range or article number for references 12, 32, 66, 108.Information of volume and page number of reference NO.12, 32 are not provided on Pubmed because they are epub ahead of print, so the doi number of these two references are added.We have added the volume and page number for reference No66, 108 according to your requirement. [DOI] [PubMed]
  • 13.Liu D, et al. Activation of the Nlrp3 inflammasome by mitochondrial reactive oxygen species: a novel mechanism of albumin-induced tubulointerstitial inflammation. Int. J. Biochem. Cell. Biol. 2014;57:7–19. doi: 10.1016/j.biocel.2014.09.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Zhuang Y, et al. Mitochondrial dysfunction confers albumin-induced NLRP3 inflammasome activation and renal tubular injury. Am. J. Physiol. Ren. Physiol. 2015;308:F857–F866. doi: 10.1152/ajprenal.00203.2014. [DOI] [PubMed] [Google Scholar]
  • 15.Wen Y, et al. mROS-TXNIP axis activates NLRP3 inflammasome to mediate renal injury during ischemic AKI. Int. J. Biochem. Cell. Biol. 2018;98:43–53. doi: 10.1016/j.biocel.2018.02.015. [DOI] [PubMed] [Google Scholar]
  • 16.Higgins GC, Coughlan MT. Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy? Br. J. Pharmacol. 2014;171:1917–1942. doi: 10.1111/bph.12503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Perry HM, et al. Dynamin-related protein 1 deficiency promotes recovery from AKI. J. Am. Soc. Nephrol. 2018;29:194–206. doi: 10.1681/ASN.2017060659. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.He P, et al. SIRT3 prevents angiotensin II-induced renal tubular epithelial-mesenchymal transition by ameliorating oxidative stress and mitochondrial dysfunction. Mol. Cell. Endocrinol. 2018;460:1–13. doi: 10.1016/j.mce.2017.04.027. [DOI] [PubMed] [Google Scholar]
  • 19.Chen JF, et al. TRAP1 ameliorates renal tubulointerstitial fibrosis in mice with unilateral ureteral obstruction by protecting renal tubular epithelial cell mitochondria. FASEB J. 2017;31:4503–4514. doi: 10.1096/fj.201700283R. [DOI] [PubMed] [Google Scholar]
  • 20.Xu Y, et al. Endoplasmic reticulum stress and its effects on renal tubular cells apoptosis in ischemic acute kidney injury. Ren. Fail. 2016;38:831–837. doi: 10.3109/0886022X.2016.1160724. [DOI] [PubMed] [Google Scholar]
  • 21.Fan Y, Lee K, Wang N, He JC. The role of endoplasmic reticulum stress in diabetic nephropathy. Curr. Diab. Rep. 2017;17:17. doi: 10.1007/s11892-017-0842-y. [DOI] [PubMed] [Google Scholar]
  • 22.Takeda N, et al. Altered unfolded protein response is implicated in the age-related exacerbation of proteinuria-induced proximal tubular cell damage. Am. J. Pathol. 2013;183:774–785. doi: 10.1016/j.ajpath.2013.05.026. [DOI] [PubMed] [Google Scholar]
  • 23.Tang X, et al. ATF6 pathway of unfolded protein response mediates advanced oxidation protein product-induced hypertrophy and epithelial-to-mesenchymal transition in HK-2 cells. Mol. Cell. Biochem. 2015;407:197–207. doi: 10.1007/s11010-015-2469-0. [DOI] [PubMed] [Google Scholar]
  • 24.Gorostizaga A, et al. Modulation of albumin-induced endoplasmic reticulum stress in renal proximal tubule cells by upregulation of mapk phosphatase-1. Chem. Biol. Interact. 2013;206:47–54. doi: 10.1016/j.cbi.2013.08.009. [DOI] [PubMed] [Google Scholar]
  • 25.He L, et al. Febuxostat attenuates ER stress mediated kidney injury in a rat model of hyperuricemic nephropathy. Oncotarget. 2017;8:111295–111308. doi: 10.18632/oncotarget.22784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Kim, Y. et al. Elevated urinary CRELD2 is associated with endoplasmic reticulum stress-mediated kidney disease. JCI Insight.2 (2017). doi:  10.1172/jci.insight.92896.Please provide the page range for references 26, 49, 58.Page number for reference NO.26 is not provided on Pubmed because it is epub ahead of print, so the doi number is added. Simliar situation applies to NO.58, the pii number is added.Page range for reference NO.49 is added according to requirement. [DOI] [PMC free article] [PubMed]
  • 27.Liu SH, et al. Chemical chaperon 4-phenylbutyrate protects against the endoplasmic reticulum stress-mediated renal fibrosis in vivo and in vitro. Oncotarget. 2016;7:22116–22127. doi: 10.18632/oncotarget.7904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Huang Y, et al. HRD1 prevents apoptosis in renal tubular epithelial cells by mediating eIF2alpha ubiquitylation and degradation. Cell Death Dis. 2017;8:3202. doi: 10.1038/s41419-017-0002-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Takahashi A, et al. Autophagy inhibits the accumulation of advanced glycation end products by promoting lysosomal biogenesis and function in the kidney proximal tubules. Diabetes. 2017;66:1359–1372. doi: 10.2337/db16-0397. [DOI] [PubMed] [Google Scholar]
  • 30.Du C, et al. Sphingosine kinase 1 protects renal tubular epithelial cells from renal fibrosis via induction of autophagy. Int. J. Biochem. Cell. Biol. 2017;90:17–28. doi: 10.1016/j.biocel.2017.07.011. [DOI] [PubMed] [Google Scholar]
  • 31.Zhou Y, et al. UCP2 attenuates apoptosis of tubular epithelial cells in renal ischemia-reperfusion injury. Am. J. Physiol. Ren. Physiol. 2017;313:F926–F937. doi: 10.1152/ajprenal.00118.2017. [DOI] [PubMed] [Google Scholar]
  • 32.Chen, G. J. et al. Urotensin II inhibits autophagy in renal tubular epithelial cells and induces extracellular matrix production in early diabetic mice. J. Diabetes Investig. (2016). doi: 10.1111/jdi.12557. [DOI] [PMC free article] [PubMed]
  • 33.Liu X, et al. Notch1 regulates PTEN expression to exacerbate renal tubulointerstitial fibrosis in diabetic nephropathy by inhibiting autophagy via interactions with Hes1. Biochem. Biophys. Res. Commun. 2018;497:1110–1116. doi: 10.1016/j.bbrc.2018.02.187. [DOI] [PubMed] [Google Scholar]
  • 34.Chandrika BB, et al. Endoplasmic reticulum stress-induced autophagy provides cytoprotection from chemical hypoxia and oxidant injury and ameliorates renal ischemia-reperfusion injury. PLoS ONE. 2015;10:e0140025. doi: 10.1371/journal.pone.0140025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Baisantry A, et al. Autophagy induces prosenescent changes in proximal tubular S3 segments. J. Am. Soc. Nephrol. 2016;27:1609–1616. doi: 10.1681/ASN.2014111059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Livingston MJ, et al. Persistent activation of autophagy in kidney tubular cells promotes renal interstitial fibrosis during unilateral ureteral obstruction. Autophagy. 2016;12:976–998. doi: 10.1080/15548627.2016.1166317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Li H, et al. Atg5-mediated autophagy deficiency in proximal tubules promotes cell cycle G2/M arrest and renal fibrosis. Autophagy. 2016;12:1472–1486. doi: 10.1080/15548627.2016.1190071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Marumo T, et al. Diabetes induces aberrant DNA methylation in the proximal tubules of the kidney. J. Am. Soc. Nephrol. 2015;26:2388–2397. doi: 10.1681/ASN.2014070665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Hewitson TD, et al. Epigenetic modifications to H3K9 in renal tubulointerstitial cells after unilateral ureteric obstruction and TGF-beta1 stimulation. Front. Pharmacol. 2017;8:307. doi: 10.3389/fphar.2017.00307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Liu N, et al. Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling. PLoS ONE. 2013;8:e54001. doi: 10.1371/journal.pone.0054001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Nguyen-Thanh T, et al. Inhibition of histone deacetylase 1 ameliorates renal tubulointerstitial fibrosis via modulation of inflammation and extracellular matrix gene transcription in mice. Int. J. Mol. Med. 2018;41:95–106. doi: 10.3892/ijmm.2017.3218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Mimura I, et al. Genome-wide analysis revealed that DZNep reduces tubulointerstitial fibrosis via down-regulation of pro-fibrotic genes. Sci. Rep. 2018;8:3779. doi: 10.1038/s41598-018-22180-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Higgins SP, et al. TGF-beta1/p53 signaling in renal fibrogenesis. Cell. Signal. 2018;43:1–10. doi: 10.1016/j.cellsig.2017.11.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Meng XM, Tang PM, Li J, Lan HY. TGF-beta/Smad signaling in renal fibrosis. Front. Physiol. 2015;6:82. doi: 10.3389/fphys.2015.00082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Ji X, et al. Specific inhibitor of Smad3 (SIS3) attenuates fibrosis, apoptosis, and inflammation in unilateral ureteral obstruction kidneys by inhibition of transforming growth factor beta (TGF-beta)/Smad3 signaling. Med. Sci. Monit. 2018;24:1633–1641. doi: 10.12659/MSM.909236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Whaley-Connell A, et al. Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin. Am. J. Nephrol. 2011;34:115–125. doi: 10.1159/000329327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Gong Q, Hou F. Silencing of angiotensin II type-1 receptor inhibits high glucose-induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells via inactivation of mTOR/p70S6K signaling pathway. Biochem. Biophys. Res. Commun. 2016;469:183–188. doi: 10.1016/j.bbrc.2015.11.092. [DOI] [PubMed] [Google Scholar]
  • 48.Eriguchi M, et al. Renal tubular ACE-mediated tubular injury is the major contributor to microalbuminuria in early diabetic nephropathy. Am. J. Physiol. Ren. Physiol. 2018;314:F531–f542. doi: 10.1152/ajprenal.00523.2017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Gewin Leslie. Renal Tubule Repair: Is Wnt/β-Catenin a Friend or Foe? Genes. 2018;9(2):58. doi: 10.3390/genes9020058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Chen L, et al. Role of RAS/Wnt/beta-catenin axis activation in the pathogenesis of podocyte injury and tubulo-interstitial nephropathy. Chem. Biol. Interact. 2017;273:56–72. doi: 10.1016/j.cbi.2017.05.025. [DOI] [PubMed] [Google Scholar]
  • 51.Lv ZM, et al. The role of the p38 MAPK signaling pathway in high glucose-induced epithelial-mesenchymal transition of cultured human renal tubular epithelial cells. PLoS ONE. 2011;6:e22806. doi: 10.1371/journal.pone.0022806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Gao F, et al. Inhibition of p38 mitogen-activated protein kinases attenuates renal interstitial fibrosis in a murine unilateral ureteral occlusion model. Life. Sci. 2016;167:78–84. doi: 10.1016/j.lfs.2016.10.022. [DOI] [PubMed] [Google Scholar]
  • 53.Du R, et al. Hypoxia-induced Bmi1 promotes renal tubular epithelial cell-mesenchymal transition and renal fibrosis via PI3K/Akt signal. Mol. Biol. Cell. 2014;25:2650–2659. doi: 10.1091/mbc.e14-01-0044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Zheng SB, Zheng Y, Jin LW, Zhou ZH, Li ZY. Microvesicles containing microRNA-21 secreted by proximal tubular epithelial cells are involved in renal interstitial fibrosis by activating AKT pathway. Eur. Rev. Med. Pharmacol. Sci. 2018;22:707–714. doi: 10.26355/eurrev_201802_14297. [DOI] [PubMed] [Google Scholar]
  • 55.Hu H, et al. miR-29b regulates Ang II-induced EMT of rat renal tubular epithelial cells via targeting PI3K/AKT signaling pathway. Int. J. Mol. Med. 2018;42:453–460. doi: 10.3892/ijmm.2018.3579. [DOI] [PubMed] [Google Scholar]
  • 56.Das F, Ghosh-Choudhury N, Venkatesan B, Kasinath BS, Ghosh Choudhury G. PDGF receptor-beta uses Akt/mTORC1 signaling node to promote high glucose-induced renal proximal tubular cell collagen I (alpha2) expression. Am. J. Physiol. Ren. Physiol. 2017;313:F291–f307. doi: 10.1152/ajprenal.00666.2016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Bera A, et al. Reciprocal regulation of miR-214 and PTEN by high glucose regulates renal glomerular mesangial and proximal tubular epithelial cell hypertrophy and matrix expansion. Am. J. Physiol. Cell. Physiol. 2017;313:C430–c447. doi: 10.1152/ajpcell.00081.2017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Kefaloyianni, E. et al. ADAM17 substrate release in proximal tubule drives kidney fibrosis. JCI Insight.1 (2016). pii: e87023. [DOI] [PMC free article] [PubMed]
  • 59.Overstreet JM, et al. Selective activation of epidermal growth factor receptor in renal proximal tubule induces tubulointerstitial fibrosis. FASEB J. 2017;31:4407–4421. doi: 10.1096/fj.201601359RR. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Tang J, et al. Sustained activation of EGFR triggers renal fibrogenesis after acute kidney injury. Am. J. Pathol. 2013;183:160–172. doi: 10.1016/j.ajpath.2013.04.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Seo E, et al. The Hippo-Salvador signaling pathway regulates renal tubulointerstitial fibrosis. Sci. Rep. 2016;6:31931. doi: 10.1038/srep31931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Du R, et al. Hypoxia-induced down-regulation of microRNA-34a promotes EMT by targeting the Notch signaling pathway in tubular epithelial cells. PLoS ONE. 2012;7:e30771. doi: 10.1371/journal.pone.0030771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Grynberg K, Ma FY, Nikolic-Paterson DJ. The JNK signaling pathway in renal fibrosis. Front. Physiol. 2017;8:829. doi: 10.3389/fphys.2017.00829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Bai Y, et al. Sonic hedgehog-mediated epithelial-mesenchymal transition in renal tubulointerstitial fibrosis. Int. J. Mol. Med. 2016;37:1317–1327. doi: 10.3892/ijmm.2016.2546. [DOI] [PubMed] [Google Scholar]
  • 65.Yang Q, Fu C, Xiao J, Ye Z. Uric acid upregulates the adiponectinadiponectin receptor 1 pathway in renal proximal tubule epithelial cells. Mol. Med. Rep. 2018;17:3545–3554. doi: 10.3892/mmr.2017.8315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Han Wei-Qing, Xu Lian, Tang Xiao-Feng, Chen Wen-Dong, Wu Yong-Jie, Gao Ping-Jin. Membrane rafts-redox signalling pathway contributes to renal fibrosis via modulation of the renal tubular epithelial-mesenchymal transition. The Journal of Physiology. 2018;596(16):3603–3616. doi: 10.1113/JP275952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Ferenbach DA, Bonventre JV. Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. Nat. Rev. Nephrol. 2015;11:264–276. doi: 10.1038/nrneph.2015.3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Bonventre JV. Primary proximal tubule injury leads to epithelial cell cycle arrest, fibrosis, vascular rarefaction, and glomerulosclerosis. Kidney Int Suppl. (2011) 2014;4:39–44. doi: 10.1038/kisup.2014.8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Andrade L, Rodrigues CE, Gomes SA, Noronha IL. Acute kidney injury as a condition of renal senescence. Cell Transplant. 2018;27:963689717743512. doi: 10.1177/0963689717743512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Yang L, Humphreys BD, Bonventre JV. Pathophysiology of acute kidney injury to chronic kidney disease: maladaptive repair. Contrib. Nephrol. 2011;174:149–155. doi: 10.1159/000329385. [DOI] [PubMed] [Google Scholar]
  • 71.Takaori K, et al. Severity and frequency of proximal tubule injury determines renal prognosis. J. Am. Soc. Nephrol. 2016;27:2393–2406. doi: 10.1681/ASN.2015060647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Schelling JR. Tubular atrophy in the pathogenesis of chronic kidney disease progression. Pediatr. Nephrol. 2016;31:693–706. doi: 10.1007/s00467-015-3169-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Clements ME, Chaber CJ, Ledbetter SR, Zuk A. Increased cellular senescence and vascular rarefaction exacerbate the progression of kidney fibrosis in aged mice following transient ischemic injury. PLoS ONE. 2013;8:e70464. doi: 10.1371/journal.pone.0070464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Lu Y, et al. Bioinformatics analysis of proteomics profiles in senescent human primary proximal tubule epithelial cells. BMC Nephrol. 2016;17:39. doi: 10.1186/s12882-016-0249-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Yu SM, Bonventre JV. Acute kidney injury and progression of diabetic kidney disease. Adv. Chronic Kidney Dis. 2018;25:166–180. doi: 10.1053/j.ackd.2017.12.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Djudjaj S, et al. Macrophage migration inhibitory factor limits renal inflammation and fibrosis by counteracting tubular cell cycle arrest. J. Am. Soc. Nephrol. 2017;28:3590–3604. doi: 10.1681/ASN.2017020190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Jenkins RH, et al. miR-192 induces G2/M growth arrest in aristolochic acid nephropathy. Am. J. Pathol. 2014;184:996–1009. doi: 10.1016/j.ajpath.2013.12.028. [DOI] [PubMed] [Google Scholar]
  • 78.Zhu F, et al. Numb contributes to renal fibrosis by promoting tubular epithelial cell cycle arrest at G2/M. Oncotarget. 2016;7:25604–25619. doi: 10.18632/oncotarget.8238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Lovisa S, et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat. Med. 2015;21:998–1009. doi: 10.1038/nm.3902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009;119:1420–1428. doi: 10.1172/JCI39104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J. Am. Soc. Nephrol. 2010;21:212–222. doi: 10.1681/ASN.2008121226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Inoue T, Umezawa A, Takenaka T, Suzuki H, Okada H. The contribution of epithelial-mesenchymal transition to renal fibrosis differs among kidney disease models. Kidney Int. 2015;87:233–238. doi: 10.1038/ki.2014.235. [DOI] [PubMed] [Google Scholar]
  • 83.Zeisberg M, Duffield JS. Resolved: EMT produces fibroblasts in the kidney. J. Am. Soc. Nephrol. 2010;21:1247–1253. doi: 10.1681/ASN.2010060616. [DOI] [PubMed] [Google Scholar]
  • 84.Humphreys BD, et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 2010;176:85–97. doi: 10.2353/ajpath.2010.090517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Liu M, et al. Hypoxia-induced activation of Twist/miR-214/E-cadherin axis promotes renal tubular epithelial cell mesenchymal transition and renal fibrosis. Biochem. Biophys. Res. Commun. 2018;495:2324–2330. doi: 10.1016/j.bbrc.2017.12.130. [DOI] [PubMed] [Google Scholar]
  • 86.Bai X, Geng J, Zhou Z, Tian J, Li X. MicroRNA-130b improves renal tubulointerstitial fibrosis via repression of Snail-induced epithelial-mesenchymal transition in diabetic nephropathy. Sci. Rep. 2016;6:20475. doi: 10.1038/srep20475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci. Signal. 2014;7:re8. doi: 10.1126/scisignal.2005189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Qureshi OS, et al. An immunofluorescence assay for extracellular matrix components highlights the role of epithelial cells in producing a stable, fibrillar extracellular matrix. Biol. Open. 2017;6:1423–1433. doi: 10.1242/bio.025866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Boor P, Floege J. Renal allograft fibrosis: biology and therapeutic targets. Am. J. Transplant. 2015;15:863–886. doi: 10.1111/ajt.13180. [DOI] [PubMed] [Google Scholar]
  • 90.Haas M. Chronic allograft nephropathy or interstitial fibrosis and tubular atrophy: what is in a name? Curr. Opin. Nephrol. Hypertens. 2014;23:245–250. doi: 10.1097/01.mnh.0000444811.26884.2d. [DOI] [PubMed] [Google Scholar]
  • 91.Hertig A, et al. Early epithelial phenotypic changes predict graft fibrosis. J. Am. Soc. Nephrol. 2008;19:1584–1591. doi: 10.1681/ASN.2007101160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Xu-Dubois YC, et al. Epithelial phenotypic changes are associated with a tubular active fibrogenic process in human renal grafts. Hum. Pathol. 2013;44:1251–1261. doi: 10.1016/j.humpath.2012.10.010. [DOI] [PubMed] [Google Scholar]
  • 93.Xu-Dubois YC, et al. Expression of the transcriptional regulator snail1 in kidney transplants displaying epithelial-to-mesenchymal transition features. Nephrol. Dial. Transplant. 2014;29:2136–2144. doi: 10.1093/ndt/gft279. [DOI] [PubMed] [Google Scholar]
  • 94.Franquesa M, et al. Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model. Stem. Cells Dev. 2012;21:3125–3135. doi: 10.1089/scd.2012.0096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Reinders ME, de Fijter JW, Rabelink TJ. Mesenchymal stromal cells to prevent fibrosis in kidney transplantation. Curr. Opin. Organ Transplant. 2014;19:54–59. doi: 10.1097/MOT.0000000000000032. [DOI] [PubMed] [Google Scholar]
  • 96.Baulier E, et al. Amniotic fluid-derived mesenchymal stem cells prevent fibrosis and preserve renal function in a preclinical porcine model of kidney transplantation. Stem Cells Transl. Med. 2014;3:809–820. doi: 10.5966/sctm.2013-0186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Sasai Y, et al. Advanced glycation endproducts stimulate renal epithelial cells to release chemokines that recruit macrophages, leading to renal fibrosis. Biosci. Biotechnol. Biochem. 2012;76:1741–1745. doi: 10.1271/bbb.120347. [DOI] [PubMed] [Google Scholar]
  • 98.Bernhardt A, et al. Inflammatory cell infiltration and resolution of kidney inflammation is orchestrated by the cold-shock protein Y-box binding protein-1. Kidney Int. 2017;92:1157–1177. doi: 10.1016/j.kint.2017.03.035. [DOI] [PubMed] [Google Scholar]
  • 99.Gewin L, Zent R, Pozzi A. Progression of chronic kidney disease: too much cellular talk causes damage. Kidney Int. 2017;91:552–560. doi: 10.1016/j.kint.2016.08.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Tan TK, et al. Matrix metalloproteinase-9 of tubular and macrophage origin contributes to the pathogenesis of renal fibrosis via macrophage recruitment through osteopontin cleavage. Lab. Invest. 2013;93:434–449. doi: 10.1038/labinvest.2013.3. [DOI] [PubMed] [Google Scholar]
  • 101.Schnaper HW. The tubulointerstitial pathophysiology of progressive kidney disease. Adv. Chronic Kidney Dis. 2017;24:107–116. doi: 10.1053/j.ackd.2016.11.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Kim SM, et al. Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy. Am. J. Physiol. Ren. Physiol. 2015;308:F993–f1003. doi: 10.1152/ajprenal.00637.2014. [DOI] [PubMed] [Google Scholar]
  • 103.Qi W, et al. High glucose induces macrophage inflammatory protein-3 alpha in renal proximal tubule cells via a transforming growth factor-beta 1 dependent mechanism. Nephrol. Dial. Transplant. 2007;22:3147–3153. doi: 10.1093/ndt/gfm365. [DOI] [PubMed] [Google Scholar]
  • 104.Baudoux T, et al. CD4(+) and CD8(+) T cells exert regulatory properties during experimental acute aristolochic acid nephropathy. Sci. Rep. 2018;8:5334. doi: 10.1038/s41598-018-23565-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Yin DD, Luo JH, Zhao ZY, Liao YJ, Li Y. Tranilast prevents renal interstitial fibrosis by blocking mast cell infiltration in a rat model of diabetic kidney disease. Mol. Med. Rep. 2018;17:7356–7364. doi: 10.3892/mmr.2018.8776. [DOI] [PubMed] [Google Scholar]
  • 106.Law BMP, et al. Interferon-gamma production by tubulointerstitial human CD56(bright) natural killer cells contributes to renal fibrosis and chronic kidney disease progression. Kidney Int. 2017;92:79–88. doi: 10.1016/j.kint.2017.02.006. [DOI] [PubMed] [Google Scholar]
  • 107.Danobeitia JS, Djamali A, Fernandez LA. The role of complement in the pathogenesis of renal ischemia-reperfusion injury and fibrosis. Fibrogenes. Tissue Repair. 2014;7:16. doi: 10.1186/1755-1536-7-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Yiu Wai Han, Li Rui Xi, Wong Dickson W L, Wu Hao Jia, Chan Kam Wa, Chan Loretta Y Y, Leung Joseph C K, Lai Kar Neng, Sacks Steven H, Zhou Wuding, Tang Sydney C W. Complement C5a inhibition moderates lipid metabolism and reduces tubulointerstitial fibrosis in diabetic nephropathy. Nephrology Dialysis Transplantation. 2017;33(8):1323–1332. doi: 10.1093/ndt/gfx336. [DOI] [PubMed] [Google Scholar]
  • 109.Xavier S, et al. Pericytes and immune cells contribute to complement activation in tubulointerstitial fibrosis. Am. J. Physiol. Ren. Physiol. 2017;312:F516–f532. doi: 10.1152/ajprenal.00604.2016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Masum MA, Ichii O, Elewa YHA, Nakamura T, Kon Y. Local CD34-positive capillaries decrease in mouse models of kidney disease associating with the severity of glomerular and tubulointerstitial lesions. BMC Nephrol. 2017;18:280. doi: 10.1186/s12882-017-0694-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Rodriguez-Romo R, et al. AT1 receptor antagonism before ischemia prevents the transition of acute kidney injury to chronic kidney disease. Kidney Int. 2016;89:363–373. doi: 10.1038/ki.2015.320. [DOI] [PubMed] [Google Scholar]
  • 112.Chen Y, Jiang S, Zou J, Zhong Y, Ding X. Silencing HIF-1alpha aggravates growth inhibition and necrosis of proximal renal tubular epithelial cell under hypoxia. Ren. Fail. 2016;38:1726–1734. doi: 10.1080/0886022X.2016.1229994. [DOI] [PubMed] [Google Scholar]
  • 113.Singh S, et al. Tubular overexpression of angiopoietin-1 attenuates renal fibrosis. PLoS ONE. 2016;11:e0158908. doi: 10.1371/journal.pone.0158908. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Kramann R, Wongboonsin J, Chang-Panesso M, Machado FG, Humphreys BD. Gli1(+) pericyte loss induces capillary rarefaction and proximal tubular injury. J. Am. Soc. Nephrol. 2017;28:776–784. doi: 10.1681/ASN.2016030297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Loeffler I, Wolf G. Epithelial-to-mesenchymal transition in diabetic nephropathy: fact or fiction? Cells. 2015;4:631–652. doi: 10.3390/cells4040631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116.Tan RJ, Zhou D, Liu Y. Kidney Dis (Basel) 2016. Signaling crosstalk between tubular epithelial cells and interstitial fibroblasts after kidney injury; pp. 136–144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117.Sakai N, et al. Lysophosphatidic acid signaling through its receptor initiates profibrotic epithelial cell fibroblast communication mediated by epithelial cell derived connective tissue growth factor. Kidney Int. 2017;91:628–641. doi: 10.1016/j.kint.2016.09.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118.Maarouf OH, et al. Paracrine Wnt1 drives interstitial fibrosis without inflammation by tubulointerstitial cross-talk. J. Am. Soc. Nephrol. 2016;27:781–790. doi: 10.1681/ASN.2014121188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119.Smith ER, Tan SJ, Holt SG, Hewitson TD. FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts. Sci. Rep. 2017;7:3345. doi: 10.1038/s41598-017-02709-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120.Zhu Q, Zeng DK, Li FQ. FGF23 promotes renal interstitial fibrosis by activating beta-catenin. Eur. Rev. Med. Pharmacol. Sci. 2018;22:174–183. doi: 10.26355/eurrev_201801_14115. [DOI] [PubMed] [Google Scholar]
  • 121.O’Connor JW, Gomez EW. Biomechanics of TGFbeta-induced epithelial-mesenchymal transition: implications for fibrosis and cancer. Clin. Transl. Med. 2014;3:23. doi: 10.1186/2001-1326-3-23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Zhou Y, et al. Secreted fibroblast-derived miR-34a induces tubular cell apoptosis in fibrotic kidney. J. Cell. Sci. 2014;127(Pt 20):4494–4506. doi: 10.1242/jcs.155523. [DOI] [PubMed] [Google Scholar]

Articles from Cell Death & Disease are provided here courtesy of Nature Publishing Group

RESOURCES